Newsletter Subject

Most important medical advance in 100 years

From

behindthemarkets.com

Email Address

newsletter@lg.behindthemarkets.com

Sent On

Wed, Apr 24, 2024 09:03 AM

Email Preheader Text

This Will Be the #1 Performing AI Stock of the Coming Decade... You are receiving this email because

This Will Be the #1 Performing AI Stock of the Coming Decade... You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please [unsubscribe]( here. --------------------------------------------------------------- The below is a message from Oxford Club. Dear Reader, In short, Artificial Intelligence is being harnessed to create breakthrough drugs no one has ever seen before. In a Wall Street Journal interview this month, Dr. Lloyd Minor, dean of the Stanford University School of Medicine, said: "The drug discovery process is on the cusp of being transformed in ways that will dramatically improve the number of therapies that get to patients ... we'll see a lot of new medicines coming out - and medicines more specific to a disease and an individual rather than medicines that are generic in terms of treatment of everyone who has the disorder. Dr. Minor concludes that AI is "a transformative moment in human history," creating the most radical and "most positive transformation in health care since the introduction of antibiotics." This is going to dramatically alter medicine forever. Keep in mind, creating a new effective drug in the past took up to 10 years and could cost up to $12 billion. But now, with artificial intelligence, it could take months and cost a fraction of that amount. And there is one particular company at the forefront of all of this. It is [the first company to bring an AI-designed drug to clinical trials](. And as a result, Big Pharma is lining up to work with them. - Merck is collaborating with them on three projects that could generate up to $674 million in revenue. - French pharma giant Sanofi agreed to pay the company up to $5.2 billion to develop 15 new drugs. - Bristol Meyers Squibb signed a $1.2 billion partnership with the company. And yet... [the company I'm talking about]( is valued at just over $600 million today. And it trades for less than $10. In other words, these deals have the potential to drive the stock many times higher in the months and years ahead. If you're looking for a great AI stock to own, [I invite you to watch my new presentation detailing the opportunity](. Good investing,  Alexander Green Chief Investment Strategist, The Oxford Club This ad is sent on behalf of The Oxford Club, 105 W. Monument Street Baltimore, MD 21201. Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our [Privacy Policy]( or our [Legal Notices.]( [Behind the Markets]( [Unsubscribe]( [invisiblelink]( Â

Marketing emails from behindthemarkets.com

View More
Sent On

13/05/2024

Sent On

13/05/2024

Sent On

13/05/2024

Sent On

12/05/2024

Sent On

12/05/2024

Sent On

11/05/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.